Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of Etentamig Plus Iberdomide in Relapsed/Refractory Multiple Myeloma
jRCT2071250057Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2025
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of etentamig and iberdomide in multiple myeloma (MM) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Dose-Limiting Toxicities (DLT) and Adverse Events (AEs). Started Aug 2025; status: recruiting.
02
Drugs
etentamigiberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2071250057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250057.